HSIANG-FONG KAOCHIA-CHI LINCHIH-HSIN YANG2020-05-262020-05-2620131479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880210838&doi=10.2217%2ffon.13.56&partnerID=40&md5=76341634ba416e90e2a6ef9ecc9d9444https://scholars.lib.ntu.edu.tw/handle/123456789/495041Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC. ? 2013 Future Medicine Ltd.[SDGs]SDG34 [4 (4' chloro 2 biphenylylmethyl) 1 piperazinyl] n [4 [3 dimethylamino 1 (phenylthiomethyl)propylamino] 3 nitrobenzenesulfonyl]benzamide; afatinib; bevacizumab; bms 099; carboplatin; cetuximab; cisplatin; dacomitinib; docetaxel; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; gemcitabine; navelbine; paclitaxel; pemetrexed; placebo; tivantinib; unclassified drug; advanced cancer; antibody dependent cellular cytotoxicity; antineoplastic activity; apoptosis; binding affinity; cancer chemotherapy; cancer combination chemotherapy; cancer survival; cell proliferation; covalent bond; crystal structure; disease exacerbation; drug cytotoxicity; drug efficacy; drug treatment failure; human; lung adenocarcinoma; lung non small cell cancer; meta analysis (topic); monotherapy; overall survival; personalized medicine; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; protein expression; quality of life; randomized controlled trial (topic); review; skin toxicity; somatic mutation; statistical significance; systemic therapy; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factorreview10.2217/fon.13.56238377622-s2.0-84880210838